Transition Therapeut (TTHI) 1.52 $TTHI OPKO Hea
Post# of 273258
Posted On: 09/02/2016 7:12:02 AM
Transition Therapeut (TTHI) 1.52 $TTHI
OPKO Health Completes Acquisition of Transition Therapeutics
BusinessWire - Wed Aug 31, 12:00AM CDT
OPKO Health, Inc. (NASDAQ: OPK), announces that it has completed its previously announced acquisition of Transition Therapeutics, Inc. (NASDAQ: TTHI, TSX: TTH), by way of a plan of arrangement (the "Arrangement"
which was approved by Transition Therapeutics' shareholders at their meeting held on August 25, 2016. Pursuant to the Arrangement, shareholders of Transition Therapeutics will receive an aggregate of approximately 6.4 million shares of OPKO common stock, or 0.1657 shares of OPKO common stock for each common share of Transition Therapeutics. The Arrangement was approved by the Ontario Superior Court of Justice in its final order dated August 29, 2016.
TTH.TO: 1.93 (+0.01), OPK: 9.29 (+0.19), TTHI: 1.52 (unch)
Transition Therapeutics Shareholders Approve Acquisition by OPKO Health
BusinessWire - Fri Aug 26, 7:52AM CDT
OPKO Health, Inc. (Nasdaq: OPK), announces that at a Special Shareholder Meeting held on August 25, 2016 shareholders of Transition Therapeutics, Inc. (NASDAQ:TTHI, TSX: TTH) holding approximately 93% of the outstanding common shares, voted to approve the previously announced agreement under which OPKO Health will acquire Transition Therapeutics. The acquisition is subject to final approval of the Ontario Superior Court Justice (the "Court". The Court hearing for the final order is scheduled to take place on August 29, 2016, and the acquisition is expected to close on September 1, 2016.
TTH.TO: 1.93 (+0.01), OPK: 9.29 (+0.19), TTHI: 1.52 (unch)
Transition Therapeutics Announces Special Shareholder Meeting Voting Results Including Shareholder Approval of the Plan of Arrangement with OPKO Health, Inc.
PR Newswire - Thu Aug 25, 5:46PM CDT
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI, TSX: TTH) is pleased to announce that the Company has received shareholder approval for the previously announced plan of arrangement involving Transition, OPKO Health, Inc., OPKO Global Holdings, Inc. and the Transition Shareholders (the "Arrangement". A total of 24,586,901 common shares, approximately 63.4% of the outstanding common shares, were represented at the meeting of Transition Shareholders (the "Meeting" in person or by proxy.
TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics Receives Notification From NASDAQ
PR Newswire - Fri Jun 03, 5:01AM CDT
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI, TSX: TTH) today announced that it received written notification from the NASDAQ Stock Market ("NASDAQ" on May 31, 2016 advising the Company that because the bid price of the Company's common shares for the previous 30 consecutive trading days had closed below the minimum $1.00 per share (the "Minimum Price Requirement" required for continued listing on the NASDAQ Global Market, the Company is not in compliance with NASDAQ Listing Rule 5450(a)(1). The notification letter has no effect on the listing of the Company's common shares at this time.
TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics posts 3Q loss
Automated Insights - Wed May 11, 3:23PM CDT
TORONTO (AP) _ Transition Therapeutics Inc. (TTHI) on Wednesday reported a loss of $3 million in its fiscal third quarter.
TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics Announces Third Quarter Fiscal 2016 Financial Results
PR Newswire - Wed May 11, 3:01PM CDT
Transition Therapeutics Inc. ("Transition" or the "Company" (TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel therapeutics for CNS, metabolic disease and androgen deficiency indications, today announced its financial results for the three and nine month periods ended March 31, 2016. Investors are invited to participate in a conference call today at 4:30pm EST to discuss these results. Dial in information for the call is as follows: (800) 698-9012 (North America) and (303) 223-4374 (International). A live webcast can be accessed via Transition's website www.transitiontherapeutics.com, with a replay available for seven days following the call.
TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2016 Financial Results on Wednesday, May 11th, at 4:30 P.M. EST
CNW Group - Mon May 09, 3:01PM CDT
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, May 11th, 2016 at 4:30 P.M. EST to discuss Third Quarter Fiscal 2016 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please call (800) 698-9012 (North America) and (303) 223-4374 (International). A webcast is also available at www.transitiontherapeutics.com A replay of the conference call will be available on Transition's website for seven days following the call.
TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics Announces Dosing of First Patient in Phase 2 Study of Drug Candidate TT701
PR Newswire - Mon Apr 25, 3:01PM CDT
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI, TSX: TTH) today announced the dosing of the first patient of a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate TT701. The Phase 2 study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency (sexual symptoms, fatigue/low vitality, and physical dysfunction) in men with prostate cancer who have undergone radical prostatectomy for organ-localized prostate cancer. Brigham and Women's Hospital (BWH) is conducting the investigator-led Phase 2 clinical study which is expected to enroll up to 125 subjects at selected specialized clinical sites including BWH. The principal investigator for the Phase 2 study is Dr. Shalender Bhasin, Director of the Research Program in Men's Health: Aging and Metabolism at BWH and an internationally recognized endocrinologist with expertise in testosterone biology and men's aging.
TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics Provides Update on Type 2 Diabetes Drug Candidate TT401
CNW Group - Mon Apr 18, 5:01AM CDT
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI, TSX: TTH) today announced that it has received notification that Eli Lilly and Co. ("Lilly" will not elect to advance diabetes drug candidate, TT401 into Phase 3 development. Under the companies' collaboration agreement, all TT401 development and commercialization rights will be transferred to Transition. Transition is unencumbered to advance TT401 on its own or with a third party.
TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics incurs lower net loss of USD2.01m in Q2 fiscal 2016
M2 - Wed Feb 10, 4:10AM CST
Biopharmaceutical company Transition Therapeutics (TSX:TTH)(NASDAQ:TTHI) stated on Tuesday that it recorded a net loss USD2.01m (USD0.05 loss per common share) for the three month period ended 31 December 2015.
TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics Announces Second Quarter Fiscal 2016 Financial Results
CNW Group - Tue Feb 09, 3:30PM CST
Transition Therapeutics Inc. ("Transition" or the "Company" (TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel therapeutics for CNS and metabolic disease indications, today announced its financial results for the three and six month periods ended December 31, 2015. Investors are invited to participate in a conference call today at 4:30pm EST to discuss these results. Dial in information for the call is as follows: (888) 227-6492 (North America) and (303) 223-2685 (International). A live webcast can be accessed via Transition's website www.transitiontherapeutics.com, with a replay available for seven days following the call.
TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2016 Financial Results on Tuesday, February 9th, at 4:30 P.M. EST
PR Newswire - Fri Feb 05, 12:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Tuesday, February 9th, 2016 at 4:30 P.M. EST to discuss Second Quarter Fiscal 2016 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please call (888) 227-6492 (North America) and (303) 223-2685 (International). A webcast is also available at www.transitiontherapeutics.com. A replay of the conference call will be available on Transition's website for seven days following the call.
TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics Announces Top Line Phase 2 Clinical Study Results of Diabetes Drug Candidate TT401
PR Newswire - Mon Feb 01, 5:01AM CST
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI, TSX: TTH) today announced the results of a Phase 2 clinical study of drug candidate TT401 (LY2944876) for the treatment of type 2 diabetes. TT401 is a once-weekly administered oxyntomodulin analog with dual GLP-1 and glucagon agonist activity. TT401 development collaborator Eli Lilly and Company performed the Phase 2 study enrolling 420 type 2 diabetes subjects into a 24 week study consisting of a 12-week randomized blinded stage followed by a 12-week open-label stage. The study included four once-weekly dose arms of TT401 (10mg, 15mg, 30mg, 50mg), a placebo arm, and an active comparator arm (exenatide extended release - 2mg).
TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch), LLY: 77.23 (-0.52)
OPKO Health Completes Acquisition of Transition Therapeutics
BusinessWire - Wed Aug 31, 12:00AM CDT
OPKO Health, Inc. (NASDAQ: OPK), announces that it has completed its previously announced acquisition of Transition Therapeutics, Inc. (NASDAQ: TTHI, TSX: TTH), by way of a plan of arrangement (the "Arrangement"
which was approved by Transition Therapeutics' shareholders at their meeting held on August 25, 2016. Pursuant to the Arrangement, shareholders of Transition Therapeutics will receive an aggregate of approximately 6.4 million shares of OPKO common stock, or 0.1657 shares of OPKO common stock for each common share of Transition Therapeutics. The Arrangement was approved by the Ontario Superior Court of Justice in its final order dated August 29, 2016. TTH.TO: 1.93 (+0.01), OPK: 9.29 (+0.19), TTHI: 1.52 (unch)
Transition Therapeutics Shareholders Approve Acquisition by OPKO Health
BusinessWire - Fri Aug 26, 7:52AM CDT
OPKO Health, Inc. (Nasdaq: OPK), announces that at a Special Shareholder Meeting held on August 25, 2016 shareholders of Transition Therapeutics, Inc. (NASDAQ:TTHI, TSX: TTH) holding approximately 93% of the outstanding common shares, voted to approve the previously announced agreement under which OPKO Health will acquire Transition Therapeutics. The acquisition is subject to final approval of the Ontario Superior Court Justice (the "Court"
. The Court hearing for the final order is scheduled to take place on August 29, 2016, and the acquisition is expected to close on September 1, 2016. TTH.TO: 1.93 (+0.01), OPK: 9.29 (+0.19), TTHI: 1.52 (unch)
Transition Therapeutics Announces Special Shareholder Meeting Voting Results Including Shareholder Approval of the Plan of Arrangement with OPKO Health, Inc.
PR Newswire - Thu Aug 25, 5:46PM CDT
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) is pleased to announce that the Company has received shareholder approval for the previously announced plan of arrangement involving Transition, OPKO Health, Inc., OPKO Global Holdings, Inc. and the Transition Shareholders (the "Arrangement". A total of 24,586,901 common shares, approximately 63.4% of the outstanding common shares, were represented at the meeting of Transition Shareholders (the "Meeting" in person or by proxy. TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics Receives Notification From NASDAQ
PR Newswire - Fri Jun 03, 5:01AM CDT
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) today announced that it received written notification from the NASDAQ Stock Market ("NASDAQ" on May 31, 2016 advising the Company that because the bid price of the Company's common shares for the previous 30 consecutive trading days had closed below the minimum $1.00 per share (the "Minimum Price Requirement" required for continued listing on the NASDAQ Global Market, the Company is not in compliance with NASDAQ Listing Rule 5450(a)(1). The notification letter has no effect on the listing of the Company's common shares at this time. TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics posts 3Q loss
Automated Insights - Wed May 11, 3:23PM CDT
TORONTO (AP) _ Transition Therapeutics Inc. (TTHI) on Wednesday reported a loss of $3 million in its fiscal third quarter.
TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics Announces Third Quarter Fiscal 2016 Financial Results
PR Newswire - Wed May 11, 3:01PM CDT
Transition Therapeutics Inc. ("Transition" or the "Company"
(TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel therapeutics for CNS, metabolic disease and androgen deficiency indications, today announced its financial results for the three and nine month periods ended March 31, 2016. Investors are invited to participate in a conference call today at 4:30pm EST to discuss these results. Dial in information for the call is as follows: (800) 698-9012 (North America) and (303) 223-4374 (International). A live webcast can be accessed via Transition's website www.transitiontherapeutics.com, with a replay available for seven days following the call. TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2016 Financial Results on Wednesday, May 11th, at 4:30 P.M. EST
CNW Group - Mon May 09, 3:01PM CDT
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, May 11th, 2016 at 4:30 P.M. EST to discuss Third Quarter Fiscal 2016 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please call (800) 698-9012 (North America) and (303) 223-4374 (International). A webcast is also available at www.transitiontherapeutics.com A replay of the conference call will be available on Transition's website for seven days following the call. TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics Announces Dosing of First Patient in Phase 2 Study of Drug Candidate TT701
PR Newswire - Mon Apr 25, 3:01PM CDT
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) today announced the dosing of the first patient of a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate TT701. The Phase 2 study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency (sexual symptoms, fatigue/low vitality, and physical dysfunction) in men with prostate cancer who have undergone radical prostatectomy for organ-localized prostate cancer. Brigham and Women's Hospital (BWH) is conducting the investigator-led Phase 2 clinical study which is expected to enroll up to 125 subjects at selected specialized clinical sites including BWH. The principal investigator for the Phase 2 study is Dr. Shalender Bhasin, Director of the Research Program in Men's Health: Aging and Metabolism at BWH and an internationally recognized endocrinologist with expertise in testosterone biology and men's aging. TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics Provides Update on Type 2 Diabetes Drug Candidate TT401
CNW Group - Mon Apr 18, 5:01AM CDT
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) today announced that it has received notification that Eli Lilly and Co. ("Lilly" will not elect to advance diabetes drug candidate, TT401 into Phase 3 development. Under the companies' collaboration agreement, all TT401 development and commercialization rights will be transferred to Transition. Transition is unencumbered to advance TT401 on its own or with a third party. TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics incurs lower net loss of USD2.01m in Q2 fiscal 2016
M2 - Wed Feb 10, 4:10AM CST
Biopharmaceutical company Transition Therapeutics (TSX:TTH)(NASDAQ:TTHI) stated on Tuesday that it recorded a net loss USD2.01m (USD0.05 loss per common share) for the three month period ended 31 December 2015.
TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics Announces Second Quarter Fiscal 2016 Financial Results
CNW Group - Tue Feb 09, 3:30PM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel therapeutics for CNS and metabolic disease indications, today announced its financial results for the three and six month periods ended December 31, 2015. Investors are invited to participate in a conference call today at 4:30pm EST to discuss these results. Dial in information for the call is as follows: (888) 227-6492 (North America) and (303) 223-2685 (International). A live webcast can be accessed via Transition's website www.transitiontherapeutics.com, with a replay available for seven days following the call. TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2016 Financial Results on Tuesday, February 9th, at 4:30 P.M. EST
PR Newswire - Fri Feb 05, 12:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) will hold a conference call on Tuesday, February 9th, 2016 at 4:30 P.M. EST to discuss Second Quarter Fiscal 2016 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please call (888) 227-6492 (North America) and (303) 223-2685 (International). A webcast is also available at www.transitiontherapeutics.com. A replay of the conference call will be available on Transition's website for seven days following the call. TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch)
Transition Therapeutics Announces Top Line Phase 2 Clinical Study Results of Diabetes Drug Candidate TT401
PR Newswire - Mon Feb 01, 5:01AM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) today announced the results of a Phase 2 clinical study of drug candidate TT401 (LY2944876) for the treatment of type 2 diabetes. TT401 is a once-weekly administered oxyntomodulin analog with dual GLP-1 and glucagon agonist activity. TT401 development collaborator Eli Lilly and Company performed the Phase 2 study enrolling 420 type 2 diabetes subjects into a 24 week study consisting of a 12-week randomized blinded stage followed by a 12-week open-label stage. The study included four once-weekly dose arms of TT401 (10mg, 15mg, 30mg, 50mg), a placebo arm, and an active comparator arm (exenatide extended release - 2mg). TTH.TO: 1.93 (+0.01), TTHI: 1.52 (unch), LLY: 77.23 (-0.52)
(0)
(0)Scroll down for more posts ▼